----
Current ValuationThe current P/E ratio is -0.14, within the reasonable range, cheaper than 52.87% of the time in the past 1 years, and the industry ranks 65/255, the industry Median -1.27.
-0.138xP/E
--Stock price
-0.138xP/E
Stock price--
Historical Valuation
P/E ratioTypical rangeMedian
- P/E ratio
- -0.14x
- Typical range
- -0.69x–-0.14x
Peer P/E ratio Comparison
It displays how the company's P/E ratio compares to top companies within its industry.
0285684112
The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.
Industry P/E ratio Comparison
This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x20x40x60x80x100x
| Name/Symbol | |||
|---|---|---|---|
TAKUSTakeda Pharmaceutical Company | -55.58x | 148.12% | $58.03B |
BAYRYUSBayer | -23.88x | -- | $48.18B |
BAYZFUSBayer Aktiengesellschaft | -24.60x | -- | $49.64B |
VTRSUSViatris | -48.91x | 107.75% | $20.09B |
ELANUSElanco Animal Health | -56.14x | 129.36% | $11.17B |
AXSMUSAxsome Therap | -47.28x | 26.61% | $9.06B |
VREOFUSVIREO GROWTH INC | -127.80x | -- | $8.58B |
CURLFUSCuraleaf Holdings, Inc. | -144.92x | -- | $7.54B |
BLTEUSBelite Bio | -61.41x | 29.87% | $6.29B |
DFTXUSDefinium Therapeutics | -13.33x | 53.61% | $4.71B |
MANEUSVeraDermics | -44.45x | 97.44% | $4.64B |
EWTXUSEdgewise Therapeutics | -21.79x | 137.29% | $4.30B |
RGCUSRegencell Bioscience | -499.79x | -- | $3.52B |
AMLXUSAmylyx Pharmaceuticals | -22.64x | 1.76% | $3.44B |
TARSUSTarsus Pharmaceuticals | -69.50x | 205.82% | $3.23B |
ELVNUSEnliven Therapeutics | -28.61x | 6.39% | $3.03B |
MBXUSMBX Biosciences | -25.19x | 31.12% | $2.63B |
SUPNUSSupernus Pharma | -22.77x | 70.59% | $2.50B |
BHCUSBausch Health | -2.09x | 307.94% | $2.30B |
PHVSUSPharvaris BV | -11.21x | 10.70% | $2.22B |
Risk Warning
Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.
